Targeting the underlying
genetic cause of disease for
UNDERSERVED
PATIENTS.

We are an integrated genetic medicines company developing targeted, disease-modifying medicines for patients with life-limiting respiratory diseases. Our treatments address the underlying genetic cause in underserved populations and have the potential to tremendously impact the quality and length of patients’ lives.
We have created a broad and customizable platform of non-viral lipid nanoparticles (LNPs), enabling us to precisely deliver our medicines safely and effectively.
With our SORT LNP delivery platform, we can hone in on previously inaccessible targets by delivering the payload precisely to a specific organ. Our proprietary delivery platforms can be customized to treat different respiratory diseases and targeted organs. Our ability to carry different types of cargo (mRNA, tRNA, CRISPR) with multiple delivery systems allows us to advance several drug candidates simultaneously. Ultimately, we match the best delivery approach to the specific problem, providing incredible flexibility in how we can potentially treat patients.
By harnessing our deep experience with well-defined drug development and regulatory pathways, we will rapidly advance our lead programs for cystic fibrosis (CF) caused by nonsense mutations and primary ciliary dyskinesia (PCD) – ultimately having a significant effect where there is a clear, unmet, and high-hurdle need.
CF and PCD are complex diseases to treat, as targeted delivery and restoration of function are big hurdles to overcome. Considering these patients are coping with a compromised quality of life and facing a significantly shortened lifespan, we must meet this need.
Our programs in CF and PCD are currently in preclinical stages of development. Our CF program is supported by a grant from the Cystic Fibrosis Foundation, whose support has allowed us to better understand the pathogenesis of CF and develop a novel therapeutic approach for correcting nonsense mutations for this severe disease.
Cystic fibrosis (CF) is a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time. In people with CF, mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause the CFTR protein to become dysfunctional, triggering the mucus in various organs to become thick and sticky. In the lungs, the mucus clogs the airways and traps germs, leading to infections, inflammation, respiratory failure and other complications. Our treatment for CF focuses specifically on the 10%-13% of CF patients who have nonsense mutations that can’t fully benefit from current small molecule therapies.
Primary ciliary dyskinesia (PCD) is a disease characterized by deficient mucociliary clearance (MCC), chronic respiratory tract infections and premature death. This rare disease is caused by mutations in more than 40 different genes that result in dysfunctional cilia and loss of MCC. PCD is a life-limiting disease with no disease-modifying treatments available to patients.
At ReCode, we bring a unique blend of rigor, creativity, and curiosity to our high-hurdle mission: harnessing our multi-platform approach to develop disease-modifying medicines. Our team is uniquely positioned to tackle this challenge, given our extensive experience in RNA delivery technologies, protein structure, tRNA biology, mRNA manufacturing, gene editing, and drug development.
Would you like to be a part of the ReCode team? Browse our open positions below.
RECODE THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
February 16, 2021
RECODE THERAPEUTICS STRENGTHENS LEADERSHIP TEAM WITH NEW APPOINTMENTS
September 9, 2020
Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing
Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing
Non‐Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co‐Delivery of Cas9 mRNA and sgRNA
PCD On the Move Virtual Scientific Conference – August 2021
William Blair Biotech Focus Conference – July 2021
LifeSci Partners Genetic Medicines Summit – June 2021
JMP Securities Life Sciences Conference – June 2021
44th European Cystic Fibrosis Conference (ECFS) presentation – June 2021
H.C. Wainwright’s Global Life Sciences Conference – March 2021
BIO CEO and Investor Digital Conference – February 2021
39th Annual J.P. Morgan Healthcare Conference Corporate Presentation – January 2021
Are you interested in learning more? Partnering with us? Joining our team?
Get in touch with us today by filling out the below contact form.
1455 Adams Drive, Suite 1120
Menlo Park, California 94025
408.585.1700
3000 Pegasus Park Drive, Bldg 6
Dallas, Texas 75247